Biogen (BIIB) Financials: History & Chart

Biogen Inc. (BIIB)BIIBBiogen Inc.

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	9.86B	2.48B	2.28B	2.45B	2.65B	2.43B	2.45B	2.47B	2.46B
Cost of Goods Sold	2.98B	661.00M	496.30M	876.60M	946.20M	577.90M	583.50M	638.70M	955.80M
Gross Profit	6.88B	1.82B	1.78B	1.58B	1.70B	1.85B	1.87B	1.83B	1.51B
Gross Profit Margin	69.8%	73.3%	78.2%	64.3%	64.2%	76.2%	76.2%	74.1%	61.2%
Total Operating Expenses	5.33B	1.42B	1.84B	964.40M	1.11B	1.12B	1.36B	1.25B	1.14B
Research & Development	1.98B	573.00M	509.30M	369.60M	529.90M	545.90M	683.50M	673.00M	592.30M
Selling, General & Administrative	2.47B	607.30M	683.00M	594.80M	581.30M	574.60M	678.70M	576.90M	550.30M
Operating Income (EBIT)	1.54B	397.40M	-57.00M	613.80M	588.10M	732.60M	509.00M	577.20M	366.50M
Operating Margin	15.6%	16.0%	-2.5%	25.0%	22.2%	30.1%	20.7%	23.4%	14.9%
Income Before Tax (EBT)	1.47B	377.70M	-211.00M	557.30M	744.00M	311.20M	291.50M	451.00M	698.70M
Interest Income	139.00M	37.90M	37.20M	31.60M	32.30M	23.90M	18.50M	11.60M	20.10M
Interest Expense	275.10M	67.60M	67.50M	67.40M	72.60M	60.00M	60.00M	59.80M	61.30M
Other Income/Expense	-74.30M	-19.70M	-154.00M	-56.50M	155.90M	-421.40M	-217.50M	-126.20M	332.20M
Net Income	1.37B	319.50M	-48.41M	466.50M	634.80M	240.50M	266.70M	388.50M	583.60M
Income Tax Expense	95.61M	58.20M	-162.59M	90.80M	109.20M	70.70M	24.80M	62.50M	115.10M
Net Profit Margin	13.9%	12.9%	-2.1%	19.0%	24.0%	9.9%	10.9%	15.8%	23.7%
EBITDA	2.43B	533.90M	298.70M	816.00M	782.40M	915.80M	693.00M	760.00M	525.40M
EBITDA Margin	24.7%	21.5%	13.1%	33.2%	29.6%	37.7%	28.2%	30.8%	21.3%
Depreciation & Amortization	888.70M	136.50M	355.70M	202.20M	194.30M	183.20M	184.00M	182.80M	158.90M
EPS Basic	9.37	2.17	-0.33	3.18	4.35	1.65	1.83	2.67	4.01
EPS Diluted	9.34	2.15	-0.33	3.17	4.35	1.64	1.83	2.66	4.00
Shares Outstanding	147.20M	147.20M	146.70M	146.60M	145.90M	145.90M	145.70M	145.70M	145.60M
Diluted Shares Outstanding	148.40M	148.40M	146.70M	147.10M	145.90M	145.90M	146.10M	145.90M	145.90M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	9.81B	9.68B	9.84B	10.17B	10.98B	13.44B	14.38B	13.45B
Cost of Goods Sold	2.90B	2.31B	2.53B	2.28B	2.11B	1.81B	1.96B	1.82B
Gross Profit	6.91B	7.37B	7.30B	7.90B	8.87B	11.64B	12.42B	11.64B
Gross Profit Margin	70.5%	76.1%	74.2%	77.6%	80.8%	86.6%	86.4%	86.5%
Total Operating Expenses	5.04B	4.88B	5.20B	5.01B	6.08B	7.05B	5.38B	5.75B
Research & Development	1.95B	2.49B	2.70B	2.60B	3.40B	4.53B	2.77B	2.71B
Selling, General & Administrative	2.43B	2.39B	2.50B	2.41B	2.68B	2.52B	2.36B	2.11B
Operating Income (EBIT)	1.88B	2.49B	2.10B	2.89B	2.79B	4.59B	7.04B	5.89B
Operating Margin	19.1%	25.7%	21.3%	28.4%	25.4%	34.2%	49.0%	43.8%
Income Before Tax (EBT)	1.40B	1.91B	1.30B	3.59B	1.78B	5.05B	7.05B	5.90B
Interest Income	87.80M	67.60M	276.50M	89.30M	11.00M	42.00M	120.00M	112.50M
Interest Expense	246.00M	250.30M	246.90M	246.60M	253.60M	222.50M	187.40M	200.60M
Other Income/Expense	-476.00M	-584.30M	-800.50M	705.30M	-1.01B	459.80M	3.90M	11.00M
Net Income	1.29B	1.63B	1.16B	3.05B	1.56B	4.00B	5.89B	4.43B
Income Tax Expense	108.11M	273.80M	135.30M	632.80M	52.50M	992.30M	1.16B	1.43B
Net Profit Margin	13.2%	16.9%	11.8%	29.9%	14.2%	29.8%	41.0%	32.9%
EBITDA	2.81B	3.16B	2.59B	3.41B	3.28B	5.05B	7.51B	6.54B
EBITDA Margin	28.7%	32.7%	26.4%	33.5%	29.9%	37.6%	52.2%	48.6%
Depreciation & Amortization	935.40M	673.20M	494.80M	518.40M	487.70M	457.20M	464.70M	650.50M
EPS Basic	8.85	11.20	8.02	20.97	10.44	24.86	31.47	21.62
EPS Diluted	8.83	11.19	7.97	20.87	10.40	24.80	31.42	21.58
Shares Outstanding	146.70M	145.70M	144.70M	145.30M	149.10M	160.90M	187.10M	204.90M
Diluted Shares Outstanding	146.70M	145.90M	145.60M	146.00M	149.60M	161.30M	187.40M	205.30M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.